Albireo Pharma

ALBO NASDAQ
25.41
+1.98
+8.43%
交易中 15:23 08/19 EDT
开盘
23.86
昨收
23.43
最高
25.87
最低
23.13
成交量
3.58万
成交均量(3M)
5.86万
52周最高
38.69
52周最低
19.10
换手率
0.28%
市值
3.22亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Albireo Pharma ALBO股票价格,Albireo Pharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
展开 >

最近浏览

名称
价格
涨跌幅